In parallel, multiplex analyses and genomic profiling have revealed that expression levels of TGF-β pathway components (e.g., SMADs, TGFBRI/II, S100A8) are closely associated with clinical stage, survival, and tumor aggressiveness. This evidence concerns the gene TGFB1 and neoplasm.